Biotechnology firm Aegle Therapeutics, which specialises in isolating extracellular vesicles (EVs) secreted by mesenchymal stem cells as therapy, has raised $4m in a funding round led by Boca Raton-based New World Angels.

Tellus BioVentures, DEFTA Healthcare Technologies and DeepWork Capital also participated in the financing round, alongside existing investors.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Proceeds from the financing will be used to fund a clinical trial to treat orphan disease Dystrophic Epidermolysis Bullosa (DEB). This trial will be the first in the US to use exosomes isolated from allogeneic mesenchymal stem cells as therapy.

DEB is a rare paediatric skin blistering disorder.

Aegle Therapeutics CEO Shelley Hartman said: “We are very excited to close this first institutional financing round with such knowledgeable, high-calibre biotech investors.

“The new funding validates our business plan and allows us to advance AGLE-102 into the clinic, as well as expand the capabilities and opportunities of this cutting-edge platform.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Aegle’s patented isolation process safely isolates EVs secreted by allogeneic bone marrow-derived mesenchymal stem cells, which are multipotent stem cells found in bone marrow. These EVs also carry certain proteins and mRNA which may prove essential for treating DEB.

According to the company, Aegle’s EVs showed a similar regenerative functionality to their parent cells in preclinical research, demonstrating the potential for cell-free therapy.

Tellus BioVentures founder Lonnie Moulder said: “We are pleased to support the advancement of this very promising science into clinical trials by Aegle’s highly capable management team.”

Aegle’s investigational new drug (IND) indicated for the treatment of patients with DEB has received clearance from the US Food and Drug Administration (FDA).

The company expects to begin DEB clinical trials in the first half of this year.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact